Who can use Retevmo(Selpercatinib)?

Retevmo (selpercatinib), as an innovative oral targeted anti-tumor drug, has a wide and precise range of indications. 

Who can use Retevmo(Selpercatinib)?

It is mainly suitable for the following three categories of patients:

1. Metastatic RET fusion-positive non-small cell lung cancer (NSCLC): For patients with metastatic RET fusion-positive NSCLC, Retevmo can effectively block tumor growth and spread, providing new treatment options for patients.

2. RET-mutated medullary thyroid cancer (MTC): For advanced or metastatic RET-mutated MTC patients who require systemic treatment, Retevmo has demonstrated significant therapeutic effects. Especially for patients with RET gene mutations, the drug can specifically inhibit tumor progression.

3. RET-positive thyroid cancer: Retevmo is also indicated for patients with advanced or metastatic RET fusion-positive thyroid cancer, particularly those who are insensitive to radioactive iodine therapy or have refractory conditions. Its application has significantly improved the survival status and quality of life of these patients.